---
title: "Halozyme COO Cortney Caudill departs amid senior management restructure"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291584433.md"
description: "Halozyme Therapeutics announced a senior management restructuring on June 30, 2026. As part of this update, Cortney Caudill is departing from her role as Senior Vice President and Chief Operating Officer."
datetime: "2026-07-02T20:11:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291584433.md)
  - [en](https://longbridge.com/en/news/291584433.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291584433.md)
---

# Halozyme COO Cortney Caudill departs amid senior management restructure

-   Halozyme announced an update to its senior management structure on June 30, 2026. \* Cortney Caudill is departing as senior vice president, chief operating officer. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001159036-26-000088), on July 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [HALO.US](https://longbridge.com/en/quote/HALO.US.md)

## Related News & Research

- [Halozyme director Bernadette Connaughton disposes of 1.626 shares worth $167.152,8](https://longbridge.com/en/news/295584667.md)
- [Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) Director Sells $167,152.80 in Stock](https://longbridge.com/en/news/295589663.md)
- [Ebusco proposes auditor switch from EY to CFA after review of audit options](https://longbridge.com/en/news/295968309.md)
- [Halozyme Buy Rating Reiterated as VYVGART Hytrulo Data Support Royalty Growth; $115 Price Target Unchanged](https://longbridge.com/en/news/296135927.md)
- [Beazley holds annual shareholder meeting in London](https://longbridge.com/en/news/295811769.md)